GLP-1 receptor agonists like semaglutide and tirzepatide dramatically reduce appetite and food preoccupation, but these same mechanisms may inadvertently reinforce restrictive eating patterns and trigger eating disorder relapses in vulnerable individuals. Current medical practice lacks systematic screening protocols to identify patients with eating disorder histories before prescribing these medications. This gap represents a significant clinical blind spot as these drugs become increasingly mainstream for weight management beyond diabetes treatment. The concern extends beyond obvious risk groups—the appetite-suppressing effects could transform previously healthy dieters into compulsive restrictors, particularly given our culture's celebration of rapid weight loss. Most troubling is the potential for these medications to mask eating disorder symptoms while they worsen, since reduced food intake appears medically beneficial in obesity treatment contexts. The eating disorders field now faces an urgent challenge: developing screening tools and monitoring protocols that can distinguish therapeutic appetite modulation from pathological restriction. This represents more than a niche clinical concern—as GLP-1 drugs expand into general weight management, millions of people with subclinical eating vulnerabilities may encounter their first trigger for full-blown eating disorders.